Table 1.
Patients’ baseline characteristics according to age
| Characteristic | Age <70 years (n = 1297) | Age ≥70 years (n = 480) | Age <75 years (n = 1571) | Age ≥75 years (n = 206) |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Male | 811 (63) | 297 (62) | 985 (63) | 123 (60) |
| Female | 486 (37) | 183 (38) | 586 (37) | 83 (40) |
| Median age, years (range) | 61 (19–69) | 73 (70–100) | 63 (19–74) | 77 (75–100) |
| ECOG performance status, n (%) | ||||
| 0 | 503 (39) | 153 (32) | 598 (38) | 58 (28) |
| 1 | 647 (50) | 251 (52) | 785 (50) | 113 (55) |
| 2 | 119 (9) | 56 (12) | 147 (9) | 28 (14) |
| 3 | 4 (<1) | 11 (2) | 11 (1) | 4 (2) |
| 4 | 0 | 1 (<1) | 1 (<1) | 0 |
| Missing | 24 (2) | 8 (2) | 29 (2) | 3 (1) |
| Metastatic site, n (%) a | ||||
| Liver | 935 (72) | 332 (69) | 1130 (72) | 137 (67) |
| Lung | 357 (28) | 133 (28) | 434 (28) | 56 (27) |
| Bone | 47 (4) | 10 (2) | 53 (3) | 4 (2) |
| Other | 350 (27) | 107 (22) | 408 (26) | 49 (24) |
| No. of metastatic sites, n (%) | ||||
| 1 | 824 (64) | 321 (67) | 1007 (64) | 138 (67) |
| >1 | 405 (31) | 124 (26) | 476 (30) | 53 (26) |
| Missing | 68 (5) | 35 (7) | 88 (6) | 15 (7) |
| Local recurrence, n (%) | 585 (51) | 220 (51) | 711 (51) | 94 (50) |
| Median CEA, ng/mL (range) | 20.9 (0–14 671) | 20.7 (0.1–25305) | 20.4 (0–25 305) | 25.6 (0.1–6848) |
| Surgical removal of primary tumour, n (%) | 1210 (93) | 442 (92) | 1464 (93) | 188 (91) |
| Prior radiotherapy, % | 18 | 14 | 18 | 12 |
| Prior chemotherapy, % | ||||
| Adjuvant | 67 | 68 | 67 | 66 |
| Neoadjuvant | 11 | 11 | 10 | 12 |
| Systolic hypertension, % | ||||
| Mild | 26 | 28 | 27 | 25 |
| Moderate | 6 | 8 | 6 | 10 |
| Severe | 1 | 1 | 1 | 1 |
| Diaystolic hypertension, % | ||||
| Mild | 17 | 14 | 17 | 12 |
| Moderate | 2 | 3 | 2 | 3 |
| Severe | 1 | 1 | 1 | 0 |
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group. aPatients could have >1 metastatic site.